Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gonadotropin-releasing hormone antagonist: how good is the new hope?
Autore:
Albano, C; Platteau, P; Devroey, P;
Indirizzi:
Dutchspeaking Brussels Free Univ, Ctr Reprod Med, B-1090 Brussels, BelgiumDutchspeaking Brussels Free Univ Brussels Belgium B-1090 ussels, Belgium
Titolo Testata:
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
fascicolo: 3, volume: 13, anno: 2001,
pagine: 257 - 262
SICI:
1040-872X(200106)13:3<257:GHAHGI>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANCER CELL-LINES; FOLLICLE-STIMULATING-HORMONE; EPIDERMAL GROWTH-FACTOR; IN-VITRO FERTILIZATION; HIGH-AFFINITY BINDING; HUMAN OVARIAN-CANCER; INVITRO FERTILIZATION; GNRH ANTAGONIST; AGONIST TRIPTORELIN; PROSTATIC-CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Albano, C Dutchspeaking Brussels Free Univ, Ctr Reprod Med, Laarbeeklaan 101, B-1090Brussels, Belgium Dutchspeaking Brussels Free Univ Laarbeeklaan 101 Brussels Belgium B-1090
Citazione:
C. Albano et al., "Gonadotropin-releasing hormone antagonist: how good is the new hope?", CUR OP OBST, 13(3), 2001, pp. 257-262

Abstract

Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assistedreproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers,such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved, Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit overgonadotropin-releasing hormone antagonists for myoma and hormone-related disorders. Curr Opin Obstet Gynecol 13:257-262. (C) 2001 Lippincott Williams& Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:35:08